Turning Pennies into dollars: (OTC: HSXI), (NYSE:ZMH), (NASDAQ: INSM).
Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://hsxi.realpennies.com
For more info: http://hsxi.realpennies.com
HealthSonix, Inc. (OTC: HSXI) (FRANKFURT: H7S)(February 5, 2008) announced yesterday that it has launched a dedicated web site for its ZingiberRx Joint and Muscle cream: www.zingiberRx.com ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.
Medical research studies into the medicinal properties of various plants in the ginger (Zingiberaceae) family have isolated the Zingiber cassumunar and Zingiber officinale species for their anti-inflammatory, anti-allergic and pain relieving properties.
"The launch of this web site coincides with on going retail sampling and couponing programs being tested in major pharmacy chains." said Dieter Doederlein, Vice President Corporate Development of HealthSonix. "The response to this new pain relieving cream, the first of its kind with ginger, continues to be very positive. We continue being a best selling topical pain reliever at those locations. "
The Company is also launching a major online sales and marketing campaign with Google and Yahoo adwords and banner ads on websites that cater to the 50+ population segment: "This new marketing program has been designed to increase awareness and promote direct to consumer sales from our online store." added Doederlein.
HealthSonix, Inc. (OTC: HSXI) (FRANKFURT: H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company's patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
For more info: http://zmh.realpennies.com
Zimmer Holdings, Inc. (NYSE and SWX: ZMH)(February 6, 2008), a leader in the orthopaedics industry, announced yesterday that it will expand its global manufacturing network by adding a 100,000 square foot plant in Shannon, Ireland.
"We are delighted to be adding a new Ireland facility to our global network," said David Dvorak, Zimmer Holdings President and CEO. "We are constantly assessing our worldwide operations and logistics network to maximize efficiency and customer service, and this project is a result of that process. We are grateful for the cooperation and encouragement of the national and local officials in Shannon and look forward to establishing a facility that utilizes the tremendous skills and expertise of the workforce to produce high technology medical devices." Zimmer said it considered a number of sites before selecting Shannon, including its existing sites and other global locations. The Company expects to invest between $70 and 75 million (USD) over the next two years in its new facility in Shannon and plans to begin manufacturing operations in late 2008. Initial employment will be approximately 25 to 50 employees, with total employment expected to be approximately 250 in five years. At start-up, the facility will produce knee replacement implants, although other products could be added in the future. Shannon Development and Irish Development Agency officials provided incentives including tax rate adjustments and training grants; the Company did not disclose actual amounts.
Making the announcement in Ireland today, Minister for Enterprise, Trade and Employment, Micheal Martin T.D., said: "Zimmer's decision to establish at Shannon Free Zone adds significantly to Ireland's profile as a leading location for medical device companies in Europe. This investment is very welcome news for Shannon and was secured by Shannon Development with the assistance of IDA Ireland. Zimmer can be confident of finding highly skilled professionals and infrastructure of international standards in this part of the country. More and more companies are discovering the benefits of locating in regional centres throughout Ireland." Shannon Development's Chief Executive, Kevin Thompstone, said: "This is a tremendous boost for Shannon; it is one of the largest projects to locate at the Shannon Free Zone in recent years. We are delighted that Zimmer have chosen Shannon. The Zimmer decision is the result of Shannon Development and IDA Ireland working to secure this project for Shannon. One of the key economic benefits of a project of this scale is the employment opportunities it presents for Irish graduates and professionals at all levels." During the past several years, the Company has expanded its Warsaw, Indiana, manufacturing, research and development, and distribution facilities, adding approximately 600 new jobs. The Company currently employs about 2,400 in Warsaw.
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer is a worldwide leader in designing, developing, manufacturing and marketing orthopaedic reconstructive, spinal and trauma devices, dental implants, and related orthopaedic surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2007 sales were approximately $3.9 billion. The Company is supported by the efforts of more than 7,500 employees worldwide. For more information about Zimmer, visit http://www.zimmer.com
For more info: http://insm.realpennies.com
Insmed Inc. (NASDAQ: INSM)(February 6, 2008), a developer of follow-on biologics and biopharmaceuticals, announced yesterday that it has launched a broad education campaign on the importance of establishing a regulatory pathway in the U.S. for large molecule protein-based drugs, known as follow-on biologics (FOBs), which are also commonly referred to as biosimilars or biogenerics.
The scientific, regulatory, and legal framework for the approval of small-molecule generic drugs is well developed, and a regulatory system for approving FOBs was established in Europe in 2006. However, no regulatory pathway currently exists for FOBs in the U.S. Insmed has launched a number of public initiatives to promote awareness of the need for Congress to establish a pathway for approval of FOBs, which would enhance patient access to and reduce costs for expensive biotech drugs. Following Insmed CEO Geoffrey Allan's recent testimony before the U.S. Congress, Insmed has initiated multiple efforts to enhance awareness of this important issue, including:
* The commissioning and upcoming release of an economic study on the savings a FOBs market would provide to patients and healthcare providers;
* An enhanced Insmed website containing enhanced FOB resources and updates;
* Interactive advocacy program utilizing user-generated content and social networking platforms;
* Stakeholder outreach and events with patient, healthcare provider, employer, and policy groups.
"We hope that this renewed attention and the inception of these initiatives will shed some light onto the significant need for Congress to adopt legislation so patients can receive affordable access to life-saving biotech drugs," said Geoffrey Allan, Ph.D., CEO of Insmed. "Given Europe's previously established regulatory pathway for FOBs, the U.S. is clearly lagging behind other nations in responding to this critical healthcare issue." "Insmed is very much at the forefront of the evolving FOB industry," continued Dr. Allan. "We have the capacity and intellectual capital to successfully develop FOBs, and are determined to continue working diligently to ensure an effective regulatory pathway is established as soon as possible, and are prepared to enter the market as soon as this becomes a reality." Insmed is currently developing a portfolio of FOBs and intends to initiate clinical trials for its first two FOBs in 2008. Members of Insmed's skilled biologics team have worked on over 50 therapeutic proteins. Their focused protein-based drug development backgrounds, coupled with the Company's FDA-approved protein manufacturing facility, and clinical and regulatory expertise, positions Insmed, upon the establishment of a regulatory pathway, to be an initial entrant into the U.S. FOBs market with a broad range of medicines following the expiration of patents covering the innovator products.
According to published reports, an estimated $10 billion worth of biologic drugs are expected to come off patent by 2010 (with an additional $10 billion by 2015). FOBs would provide safe and effective therapies at a reduced cost following the expiration of the original product's patent.
About Insmed
Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. Insmed has a state-of-the-art, FDA-approved biologic commercial manufacturing facility in Boulder, Colorado and a Corporate office in Richmond, Virginia. For more information, please visit http://www.insmed.com.
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
Sponsored by: http://www.isthemarketopen.com
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
No comments:
Post a Comment